Shots: Novartis to receive $13B (£9.2B) as total deal value from GSK. GSK to acquire 36.5% stake (63.5% already acquired in 2014) in Consumer Healthcare Joint Venture, formed in 2014 […]readmore
Shots: Novartis acquires AveXis, in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B The focus of […]readmore
Shots: Celgene acquires Juno, in all stock transaction with its JCAR017& JCARH125 clinical products. Juno to receive $87/share in cash, making total deal value as $9B The focus of the […]readmore
Shots: Sanofi acquires Bioverativ, in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value […]readmore